181 related articles for article (PubMed ID: 17164297)
1. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study.
Rubino A; Roskell N; Tennis P; Mines D; Weich S; Andrews E
BMJ; 2007 Feb; 334(7587):242. PubMed ID: 17164297
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of risk factors for suicide in patients prescribed venlafaxine, fluoxetine, and citalopram.
Mines D; Hill D; Yu H; Novelli L
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):367-72. PubMed ID: 15883980
[TBL] [Abstract][Full Text] [Related]
3. Antidepressants and the risk of suicidal behaviors.
Jick H; Kaye JA; Jick SS
JAMA; 2004 Jul; 292(3):338-43. PubMed ID: 15265848
[TBL] [Abstract][Full Text] [Related]
4. Prescribing of venlafaxine and dosulepin in primary care.
McAllister-Williams RH; Foran K; Forrest S; Ingram G; McMahon L; Taylor M; Rajwal MS; Cornwall PL
J Psychopharmacol; 2006 Nov; 20(6):868. PubMed ID: 17060347
[No Abstract] [Full Text] [Related]
5. Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: a nested case-control study.
Martinez C; Assimes TL; Mines D; Dell'aniello S; Suissa S
BMJ; 2010 Feb; 340():c249. PubMed ID: 20139216
[TBL] [Abstract][Full Text] [Related]
6. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data.
Schneeweiss S; Patrick AR; Solomon DH; Mehta J; Dormuth C; Miller M; Lee JC; Wang PS
Arch Gen Psychiatry; 2010 May; 67(5):497-506. PubMed ID: 20439831
[TBL] [Abstract][Full Text] [Related]
7. Suicide risk and choice of antidepressant.
Davis A; Gilhooley M; Agius M; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):358-9. PubMed ID: 20562782
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant use during pregnancy. FPIN’s clinical inquiries.
Patel BN; Beste J; Blackwell JC
Am Fam Physician; 2011 May; 83(10):1211-5. PubMed ID: 21568258
[No Abstract] [Full Text] [Related]
9. Antidepressant use and risk of suicide and attempted suicide or self harm in people aged 20 to 64: cohort study using a primary care database.
Coupland C; Hill T; Morriss R; Arthur A; Moore M; Hippisley-Cox J
BMJ; 2015 Feb; 350():h517. PubMed ID: 25693810
[TBL] [Abstract][Full Text] [Related]
10. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.
Whyte IM; Dawson AH; Buckley NA
QJM; 2003 May; 96(5):369-74. PubMed ID: 12702786
[TBL] [Abstract][Full Text] [Related]
11. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression.
Mahapatra SN; Hackett D
Int J Clin Pract; 1997 Jun; 51(4):209-13. PubMed ID: 9287259
[TBL] [Abstract][Full Text] [Related]
12. Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine.
Entsuah R; Gorman JM
J Psychiatr Res; 2002; 36(3):111-8. PubMed ID: 11886688
[TBL] [Abstract][Full Text] [Related]
13. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
[TBL] [Abstract][Full Text] [Related]
14. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Bauer M; Tharmanathan P; Volz HP; Moeller HJ; Freemantle N
Eur Arch Psychiatry Clin Neurosci; 2009 Apr; 259(3):172-85. PubMed ID: 19165525
[TBL] [Abstract][Full Text] [Related]
15. Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
Gibbons RD; Brown CH; Hur K; Davis J; Mann JJ
Arch Gen Psychiatry; 2012 Jun; 69(6):580-7. PubMed ID: 22309973
[TBL] [Abstract][Full Text] [Related]
16. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Brent DA; Emslie GJ; Clarke GN; Asarnow J; Spirito A; Ritz L; Vitiello B; Iyengar S; Birmaher B; Ryan ND; Zelazny J; Onorato M; Kennard B; Mayes TL; Debar LL; McCracken JT; Strober M; Suddath R; Leonard H; Porta G; Keller MB
Am J Psychiatry; 2009 Apr; 166(4):418-26. PubMed ID: 19223438
[TBL] [Abstract][Full Text] [Related]
17. [Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)].
Hjalmarsson L; Corcos M; Jeammet P
Encephale; 2005; 31(3):309-16. PubMed ID: 16142045
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antidepressant effects of venlafaxine and dosulepin in a naturalistic setting.
Bukh JD; Jørgensen MB; Dam H; Plenge P
Nord J Psychiatry; 2009; 63(4):347-51. PubMed ID: 19347769
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.
Sánchez C; Hyttel J
Cell Mol Neurobiol; 1999 Aug; 19(4):467-89. PubMed ID: 10379421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
